-
Response to Deantoni et al. Tumori J. (IF 1.9) Pub Date : 2024-03-12 Erkan Topkan, Efsun Somay, Ugur Selek
-
Management of cancer treatment–induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey Tumori J. (IF 1.9) Pub Date : 2024-03-11 Anna Amela Valsecchi, Vittorio Fusco, Massimo Di Maio, Daniele Santini, Marcello Tucci, Ugo De Giorgi, Rossana Dionisio, Francesca Vignani, Saverio Cinieri
Purpose:Cancer treatment–induced bone loss is a side effect of hormonal therapy that can severely affect patients' quality of life. The aim of this survey was to obtain an updated picture of management of bone health in patients with breast cancer undergoing adjuvant hormonal therapy and in patients with hormone sensitive prostate cancer according to Italian oncologists.Methods:Our survey was made
-
How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved checkpoint immune inhibitors? Tumori J. (IF 1.9) Pub Date : 2024-02-19 Emanuele Crocetti, Alessandra Ravaioli, Fabio Falcini, Rosa Vattiato, Silvia Mancini, Flavia Baldacchini, Federica Zamagni, Benedetta Vitali, Chiara Balducci, Lauro Bucchi, Orietta Giuliani
Introduction:This cross-sectional study was aimed at estimating the number of Italian incident cancer patients in 2020 eligible for, and respondent to, immune checkpoint inhibitors (ICI).Methods:The study is based on publicly available data: the ICI approved until August 2022 by the Italian Medicines Agency (AIFA) with their specific indications and overall observed responses, rther details can be
-
Melanoma and sex hormones: Pathogenesis, progressive disease and response to treatments Tumori J. (IF 1.9) Pub Date : 2024-02-19 Ida Taglialatela, Alice Indini, Giulia Santanelli, Giorgia Di Liberti, Lorenza Di Guardo, Filippo De Braud, Michele Del Vecchio
Cutaneous melanoma represents the fifth tumor in terms of incidence in young adults, with a major involvement of males than females. Despite the significant changes in available effective treatments for cutaneous melanoma, there is still a proportion of patients that do not benefit long-term disease control with immune checkpoint inhibitors and/or BRAF/MEK inhibitors, and eventually develop progressive
-
Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund Tumori J. (IF 1.9) Pub Date : 2024-02-19 Luigi Cerbone, Sara Delfanti, Stefania Crivellari, Antonina Maria De Angelis, Laura Mazzeo, Claudia Proto, Mario Occhipinti, Giuseppe Lo Russo, Chiara Dellepiane, Federica Biello, Irene Alabiso, Francesco Verderame, Roberta Gauna, Irene De Simone, Federica Cuppone, Sandra Petraglia, Giulia Pasello, Giovanni Luca Ceresoli, Marina Chiara Garassino, Valter Torri, Federica Grosso
Background:Pleural mesothelioma is a rare cancer with a dismal prognosis and few therapeutic options, especially in the pretreated setting. Immunotherapy with checkpoint inhibitors as single agents yielded interesting results in refractory pleural mesothelioma, achieving a response rate between 10-20%, median progression-free survival of 2-5 months and median overall survival of 7-13 months.Patients
-
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO) Tumori J. (IF 1.9) Pub Date : 2024-02-08 Desirèe Speranza, Elena Sapuppo, Giuseppe Aprile, Alessandra Auriemma, Francesca Bergamo, Roberto Bianco, Roberto Bordonaro, Giovanni Brandi, Oronzo Brunetti, Carlo Carnaghi, Domenico Ciliberto, Saverio Cinieri, Salvatore Corallo, Ferdinando De Vita, Samantha Di Donato, Francesco Ferraù, Lorenzo Fornaro, Viola Barucca, Elisa Giommoni, Claudio Lotesoriere, Claudio Luchini, Cristina Masini, Monica Niger
Introduction:About 90% of cholangiocarcinomas are adenocarcinomas with glandular or tubular structures lined by epithelial cells, with no bile production and with a variable degree of differentiation, arising in the background of desmoplastic stroma. The remaining 10% is represented by rarer histological variants of which there is little knowledge regarding the biological behavior, molecular characterization
-
Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis Tumori J. (IF 1.9) Pub Date : 2024-01-06 Min Zhao, Lixing Wang, Xingyu Wang, Juan He, Kuai Yu, Dan Li
The microenvironment of diffuse large B-cell lymphoma (DLBCL) is composed of various components, including immune cells and immune checkpoints, some of which have been correlated with the prognosis of DLBCL, but their results remain controversial. Therefore, we conducted a systematic review and meta-analysis to investigate the association between the microenvironment and prognosis in DLBCL. We searched
-
Is motherhood still possible after pelvic carbon ion radiotherapy? A promising combined fertility-preservation approach Tumori J. (IF 1.9) Pub Date : 2024-01-06 Amelia Barcellini, Chiara Cassani, Ester Orlandi, Rossella E. Nappi, Federica Broglia, Maria Paola Delmonte, Silvia Molinelli, Alessandro Vai, Viviana Vitolo, Alessandro Gronchi, Gioacchino D’Ambrosio, Lorenzo Cobianchi, Maria Rosaria Fiore
Introduction:Preserving the endocrine and reproductive function in young female cancer patients undergoing pelvic radiation is a significant challenge. While the photon beam radiation's adverse effects on the uterus and ovaries are well established, the impact of pelvic carbon ion radiotherapy on women's reproductive function is largely unexplored. Strategies such as oocyte cryopreservation and ovarian
-
Hippocampal region avoidance in whole brain radiotherapy in brain metastases: For all or for some? A real-world feasibility report Tumori J. (IF 1.9) Pub Date : 2024-01-06 Giulia Corrao, Luca Bergamaschi, Vanessa Eleonora Pierini, Aurora Gaeta, Stefania Volpe, Matteo Pepa, Mattia Zaffaroni, Maria Giulia Vincini, Cristiana Iuliana Fodor, Gaia Piperno, Francesca Emiro, Annamaria Ferrari, Sara Gandini, Federica Cattani, Roberto Orecchia, Giulia Marvaso, Barbara Alicja Jereczek-Fossa
Purpose:Hippocampal sparing whole-brain radiotherapy (HS-WBRT) showed significantly lower long-term side effects compared to standard WBRT. Aim of this study is to describe a HS-WBRT real-world monoinstitutional experience within a retrospective cohort.Methods:Patients who completed HS-WBRT course, with Karnofsky Performance Status ⩾ 60 and radiological diagnosis of brain metastases (BMs) were enrolled
-
HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: A focus on the potential role of vaccination. Tumori J. (IF 1.9) Pub Date : 2023-11-17 Giorgio Bogani,Francesco Sopracordevole,Andrea Ciavattini,Alessandro Ghelardi,Enrico Vizza,Paolo Vercellini,Jvan Casarin,Ciro Pinelli,Fabio Ghezzi,Rosa De Vincenzo,Violante Di Donato,Tullio Golia D'augè,Andrea Giannini,Flavia Sorbi,Marco Petrillo,Giampiero Capobianco,Giuseppe Vizzielli,Stefano Restaino,Stefano Cianci,Giovanni Scambia,Francesco Raspagliesi
OBJECTIVE To date, no data supports the execution of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia (CIN2+) and early-stage cervical cancer. We aim to evaluate the potential effect of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer. METHODS This is a multi-center retrospective study evaluating data of
-
Impact of low skeletal muscle mass in oropharyngeal cancer patients treated with radical chemo-radiotherapy: A mono-institutional experience. Tumori J. (IF 1.9) Pub Date : 2023-11-17 Chiara L Deantoni,Aurora Mirabile,Anna Chiara,Laura Giannini,Martina Midulla,Antonella Del Vecchio,Claudio Fiorino,Andrei Fodor,Nadia G Di Muzio,Italo Dell'Oca
AIMS Low skeletal muscle mass index (SMI) has recently emerged as an independent prognostic factor in oncological patients and it is linked with poor survival and higher treatment toxicity. The present study aims to determine the possible impact of low SMI on survival and acute toxicity in oropharyngeal patients. METHODS Seventy-six patients with locally advanced oropharyngeal squamous cell carcinoma
-
Management of primary and recurrent Bartholin's gland carcinoma: A systematic review on behalf of MITO Rare Cancer Group. Tumori J. (IF 1.9) Pub Date : 2023-11-13 Camilla Turetta,Roberta Mazzeo,Giuseppe Capalbo,Salvatora Miano,Robert Fruscio,Violante Di Donato,Francesca Falcone,Giorgia Mangili,Sandro Pignata,Innocenza Palaia
Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin's gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in
-
A shared vaccination ambulatory for patients with cancer in Udine, Italy. Tumori J. (IF 1.9) Pub Date : 2023-10-30 Francesca Valent,Giulia Degani,Monica Gri,Raffaela Donato,Giulia Varadi,Giovanni Gerardo Cardellino,Gianpiero Fasola
-
A locally advanced colon cancer patient with Muir-Torre syndrome obtains durable response to neoadjuvant and adjuvant immunotherapy. Tumori J. (IF 1.9) Pub Date : 2023-10-26 Zhihua Guo,Yue Cai,Weiqiang Yin,Jun Huang
INTRODUCTION Muir-Torre syndrome, presenting with cutaneous tumors and visceral malignancies, is a variant of Lynch syndrome. The development of immune checkpoint inhibitors provided novel effective treatment options for metastatic colorectal cancer patients with microsatellite instability and deficient mismatch repair. However, the use of immune checkpoint inhibitors in neoadjuvant and adjuvant settings
-
Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort. Tumori J. (IF 1.9) Pub Date : 2023-10-11 Andrea Olsen,Alexandra Lebedeva,Polina Nosova,Vladislav Nikulin,Margarita Sharova,Ekaterina Ignatova,Vladislav Mileyko,Maxim Ivanov
INTRODUCTION Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort. METHODS We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular
-
Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting. Tumori J. (IF 1.9) Pub Date : 2023-09-29 Ugo Testa,Germana Castelli,Elvira Pelosi
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine
-
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey. Tumori J. (IF 1.9) Pub Date : 2023-09-19 Bruna Cerbelli,Alessio Cirillo,Giulia Pomati,Angelina Pernazza,Andrea Ascione,Simona Pisegna,Annalinda Pisano,Martina Leopizzi,Maria Gemma Pignataro,Leopoldo Costarelli,Antonino Mulè,Andrea Vecchione,Piera Catalano,Luigi Coppola,Giuseppe Perrone,Letizia Perracchio,Lucia Anemona,Antonio Mastracchio,Stefano Nardi,Renato Reitano,Annalisa Massari,Lucia Rosalba Grillo,Fabrizio Liberati,Carlo Della Rocca
BACKGROUND Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period
-
De novo germline pathogenic variant in Lynch Syndrome: A rare event or the tip of the iceberg? Tumori J. (IF 1.9) Pub Date : 2023-09-11 Clorinda Brignola,Sara Volorio,Giovanna De Vecchi,Daniela Zaffaroni,Valentina Dall'Olio,Frederique Mariette,Domenico Sardella,Fabio Capra,Stefano Signoroni,Emanuele Rausa,Marco Vitellaro,Valeria Pensotti,Maria Teresa Ricci
Lynch Syndrome is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants or epimutation in one of the DNA mismatch repair genes. De novo pathogenic variants in mismatch repair genes have been described as a rare event in Lynch Syndrome (1-5%), although the prevalence of de novo pathogenic variants in Lynch Syndrome is probably underestimated. The de novo pathogenic
-
There is no such a thing as a 'biological' basis for cancer disparities: A call to end misreporting of the ultimate determinants of health outcomes. Tumori J. (IF 1.9) Pub Date : 2023-09-09 Dario Trapani,Fabio Girardi,Saverio Cinieri,Giuseppe Curigliano
Improved strategies of cancer prevention and control have resulted in tangible benefits for patients with cancer. Disparities in outcome have been reported as a result of inequal access to health care. Historically, differences in health outcomes at population level have been reported according to key characteristics, including race, ethnicity and, more recently, ancestry. These population descriptors
-
Periprosthetic effusions surrounding breast expander: a flow cytometric, immunohistochemical and molecular characterization. Tumori J. (IF 1.9) Pub Date : 2023-08-14 Laura Sala,Chiara Maura Ciniselli,Fabio Bozzi,Valeria Summo,Chiara Bonini,Silvia Brich,Alessia Bertolotti,Trupia Desiré Viola,Chiara Costanza Volpi,Sara Pizzamiglio,Biagio Paolini,Antonella Aiello,Giovanni Apolone,Paolo Verderio,Umberto Cortinovis
INTRODUCTION The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions
-
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology. Tumori J. (IF 1.9) Pub Date : 2023-08-10 Angioletta Lasagna,Antonella Brunello,Nicola Silvestris,Paolo Pedrazzoli,Massimo Di Maio,Saverio Cinieri
BACKGROUND Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022
-
A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients. Tumori J. (IF 1.9) Pub Date : 2023-08-09 Jianjun Ye,Xinyang Liao,Yu Qiu,Qiang Wei,Yige Bao
OBJECTIVE The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis. MATERIALS AND METHODS A systematically computerized search in PubMed, Scopus
-
Mind the gap with Europe. Why public interest cannot be a good reason to perform observational and epidemiological research? Tumori J. (IF 1.9) Pub Date : 2023-08-07 Celeste Cagnazzo,Bruno Ficara,Federica Palermo,Franca Fagioli
The consequences of the Italian privacy legislation, that represents a very restrictive implementation of the general European regulation on data protection, have mainly been felt at the level of observational research. In this field is not always possible to obtain the consent of subjects, and as for retrospective studies, it is not currently clear which is the correct regulatory procedure to follow
-
Role of enhancement modifications in evaluating tumor response to immunotherapy in metastatic renal cell carcinoma. Tumori J. (IF 1.9) Pub Date : 2023-07-28 Michele Dionese,Francesco Pierantoni,Elisabetta Bezzon,Enrico Cumerlato,Davide Bimbatti,Umberto Basso,Marco Maruzzo,Vittorina Zagonel
INTRODUCTION Evaluation of tumor response according only to dimensional criteria may underestimate treatment benefit in patients treated for metastatic renal cell carcinoma (RCC). In this study we evaluated the role of lesion enhancement modifications and Choi criteria in patients affected by renal cell carcinoma treated with immunotherapy. METHODS We collected data of 60 consecutive patients (with
-
Have we made progress in taking care of adolescents and young adults with cancer? Results of a European multi-professional survey. Tumori J. (IF 1.9) Pub Date : 2023-07-24 Ivana Bozovic Spasojevic,Andrea Ferrari,Johan De Munter,Ashley Gamble,Assia Konsoulova-Kirova,Katie Rizvi,Carina Schneider,Marie Balsat,Anna Castleton,Leila Gofti-Laroche,Anita Kienesberger,Beate Timmermann,Josef Vormoor,Emmanouil Saloustros,Daniel P Stark
BACKGROUND It is well documented that traditional health care models do not meet the specific needs of Adolescents and Young Adults (AYA) cancer patients. METHODS We explore a map of the development of age-specific AYA cancer care across Europe, from the perspective of healthcare professionals with an interest in AYA care, in order to understand the specific challenges and map progress over time. An
-
Current practices of follow-up programs for childhood cancer survivors in Italy. Tumori J. (IF 1.9) Pub Date : 2023-07-12 Monica Terenziani,Alberto Eugenio Tozzi,Laura Diaco,Eleonora Biasin,Alessandro Cattoni,Ileana Croci,Donatella Fraschini,Giovanna Giorgiani,Riccardo Haupt,Monica Muraca,Marta Pillon,Giovanna Sironi,Maria Grazia Valsecchi,Angela Mastronuzzi
INTRODUCTION Quality of life in childhood cancer survivors is largely affected by survivorship care and transition from treatment to long-term follow-up (LTFU). Referring to evidence-based recommendations, we wanted to evaluate LTFU care for survivors through a survey among the Italian Association for Pediatric Hematology-Oncology (AIEOP) centers. The project aimed to evaluate the availability of services
-
Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib. Tumori J. (IF 1.9) Pub Date : 2023-07-07 Massimo Aglietta,Vanna Chiarion-Sileni,Paolo Fava,Massimo Guidoboni,Roberta Depenni,Alessandro Minisini,Francesca Consoli,Paolo Antonio Ascierto,Gaetana Rinaldi,Maria Banzi,Riccardo Marconcini,Rossana Gueli,Virginia Ferraresi,Marco Tucci,Giuseppe Tonini,Giovanni Lo Re,Michele Guida,Michele Del Vecchio,Ilaria Gioia Marcon,Paola Queirolo
BACKGROUND Brain metastases (BM) and lactate dehydrogenase (LDH) levels above the upper limit of normal (ULN) are associated with poor prognosis in patients with melanoma. Although treatment with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib have demonstrated long-term clinical benefit in patients with melanoma, data on their efficacy in patients with BM are limited. METHODS DESCRIBE
-
-
Complete pathological response of hormone receptor positive invasive breast cancer in a patient with multiple myeloma treated with ixazomib. Tumori J. (IF 1.9) Pub Date : 2023-06-02 Martina Dameri,Alessandro Garlaschi,Paola Cuccarolo,Andrea Ceccardi,Mario Stabile,Irene Valente,Licia Gristina,Massimo Calabrese,Alberto Ballestrero,Alberto Tagliafico,Gabriele Zoppoli
Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of
-
Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma. Tumori J. (IF 1.9) Pub Date : 2023-05-30 Yuanshan Yao,Haojie Xuan,Jing Wang,Libao Gong,Wen Gao
BACKGROUND Esophageal squamous cell carcinoma (ESCC) is one of the most common upper gastrointestinal malignancies worldwide. Tertiary lymphoid structures (TLS) are tumor-infiltrating immune cells aggregates coupled with stromal cells which are similar to secondary lymphoid organs. The objective of this study is to explore the predictive effects of two common genes associated with TLS models on prognosis
-
Electronic cigarette, or vaping, product use-associated lung injury (EVALI) in a patient with testicular cancer: A case report Tumori J. (IF 1.9) Pub Date : 2023-05-10 Jacob Stein, Hannah E Kay, Jeremy Sites, Afsaneh Pirzadeh, Benny L Joyner, Jr., Toni Darville, Marc A Bjurlin, Tracy L Rose, Ilona Jaspers, Matthew I Milowsky
Electronic cigarette, or vaping, product use-associated lung injury (EVALI) is an increasingly recognized entity with the potential for severe pulmonary toxicity. We present the case of a young man...
-
End-of-Life transfusion support at hospice and pediatric oncology unit: Bridging the gap between benefits and therapeutic alliance Tumori J. (IF 1.9) Pub Date : 2023-05-08 Olga Nigro, Marta G Podda, Federico Pellegatta, Elisabetta Schiavello, Carlo A Clerici, Igor Catalano, Giovanna Visconti, Marco Albarini, Roberto Luksch, Monica Terenziani, Andrea Ferrari, Michela Casanova, Veronica Biassoni, Cristina Meazza, Filippo Spreafico, Giovanna Gattuso, Giovanna Sironi, Nadia Puma, Luca Bergamaschi, Stefano Chiaravalli, Maura Massimino
Objectives:Although transfusion support is commonly used in oncological palliative care, there is still a paucity of literature. We examined the transfusion support provided in the terminal stage o...
-
Oral vinorelbine in young patients with desmoid-type fibromatosis Tumori J. (IF 1.9) Pub Date : 2023-04-28 Laure Kornreich, Daniel Orbach, Nayla Nicolas, Hervé J Brisse, Pablo Berlanga, Anne-Sophie Defachelles, Ludovic Mansuy, Cécile Verite, Laure Saumet, Marie Karanian, Nadège Corradini
Background:Desmoid-type fibromatosis are rare intermediate tumors in children and adolescents. Owing to local aggressiveness and relapse, systemic treatment for symptomatic advanced or progressive ...
-
Observational studies - The Cinderella of the Italian research system Tumori J. (IF 1.9) Pub Date : 2023-04-08 Celeste Cagnazzo, Marco Basiricò, Federica Palermo, Franca Fagioli
Observational trials are crucial to assess the generalizability in the real world of evidence deriving from registration studies. Despite the unquestionable importance of this type of studies, Ital...
-
Advancing biomarker development for diagnostics and therapeutics using solid tumour cancer stem cell models Tumori J. (IF 1.9) Pub Date : 2023-03-24 Samuel Sherng Young Wang
The cancer stem cell model hopes to explain solid tumour carcinogenesis, tumour progression and treatment failure in cancers. However, the cancer stem cell model has led to minimal clinical transla...
-
Treating secondary malignant neoplasms: A burden of childhood cancer survivors Tumori J. (IF 1.9) Pub Date : 2023-03-24 Marta G Podda, Cristina Meazza, Giovanna Gattuso, Giovanna Sironi, Olga Nigro, Luca Bergamaschi, Veronica Biassoni, Michela Casanova, Stefano Chiaravalli, Andrea Ferrari, Roberto Luksch, Nadia Puma, Elisabetta Schiavello, Filippo Spreafico, Paolo Grampa, Siranoush Manoukian, Sabina Vennarini, Paola Collini, Primo A Daolio, Massimiliano Gennaro, Marco Guzzo, Carlo Morosi, Davide Biasoni, Maura Massimino
Each year approximately 35,000 children and adolescents are diagnosed with cancer in Europe. Five-year survival rates have improved and now reach 80% in most European countries, thanks to a combina...
-
New perspectives: glioma in adult patients Tumori J. (IF 1.9) Pub Date : 2023-03-24 Antonio Silvani
The purpose of this editorial is to consider some of the aspects of the diagnosis and treatment of adult gliomas. These are rare diseases with all their limitations. Innovations in diagnosis and th...
-
Can Ki-67 predict radiotherapy response in neuroendocrine tumors? Retrospective analysis of a monocentric series of patients Tumori J. (IF 1.9) Pub Date : 2023-03-20 Dario Zerini, Marco Rotondi, Stefania Volpe, Eleonora Pisa, Emanuele Frigo, Cristiana Pedone, Michele Flospergher, Vincenzo Bagnardi, Samuele Frassoni, Cristiana Iuliana Fodor, Francesca Spada, Nicola Fazio, Daniela Alterio, Barbara Alicja Jereczek-Fossa
BackgroundThe impact of radiotherapy (RT) in neuroendocrine neoplasms is still unknown, and outcomes could be improved by a better insight in RT response predictors. This retrospective analysis inv...
-
Breast implant associated anaplastic large cell lymphoma: Evidence for an efficient diagnostic workup Tumori J. (IF 1.9) Pub Date : 2023-03-20 Laura Vittoria, Laura Sala, Valeria Summo, Iolanda Capone, Elena Conca, Martina Toma, Joseph Ottolenghi, Francesca Testa, Umberto Cortinovis, Biagio Paolini, Antonello Cabras, Antonella Aiello, Fabio Bozzi
Introduction:During the last few years it has been shown that an anaplastic T cell lymphoma can develop as a rare and late sequelae of implant-based breast reconstruction. This malignancy was recog...
-
Acute myeloid leukemia: Incidence, transplantation and survival through Italian administrative healthcare data Tumori J. (IF 1.9) Pub Date : 2023-03-09 Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Giuseppe Rossi, Felicetto Ferrara, Adriano Venditti, Nello Martini
Objective:To identify newly diagnosed patients with acute myeloid leukemia in 2017 treated with intensive chemotherapy or unfit for intensive chemotherapy, and to assess their probability of receiv...
-
The Oncohumanities training programme: Fostering a deeper engagement and integration of oncology and humanities to tackle the pressing and complex challenges of cancer care Tumori J. (IF 1.9) Pub Date : 2023-03-09 Daniele Carrieri, Fedro Alessandro Peccatori, Giovanni Boniolo
‘Oncohumanities’ is a new field of oncology and humanities which integrates a rich gamut of humanity disciplines and oncological expertise to tackle patients’ real needs and priorities. To promote ...
-
Upper-neck irradiation versus standard whole-neck irradiation in nasopharyngeal carcinoma: A systematic review and meta-analysis Tumori J. (IF 1.9) Pub Date : 2023-02-16 Francesca De Felice, Claudia Marchetti, Maria Serpone, AnnaMaria Camarda, Barbara Vischioni, Rossana Ingargiola, Daniela Musio, Ester Orlandi
Purpose:To evaluate the role of upper-neck irradiation versus standard whole-neck irradiation in patients with N0-1 nasopharyngeal carcinoma.Methods:We conducted a PRISMA guideline based systematic...
-
Long term outcome of complex surgical resection and reconstruction for rare thoracic cancers Tumori J. (IF 1.9) Pub Date : 2023-02-16 Ugo Pastorino, Giovanni Leuzzi, Federica Sabia, Paolo Girotti, Leonardo Duranti, Stefano Radaelli, Marco Fiore, Silvia Stacchiotti, Giannatempo Patrizia, Roberto Salvioni, Alessandro Gronchi
BackgroundComplex surgical resection and reconstruction for rare thoracic cancers (RTCs) represent a major challenge, given their very low frequency, extreme variability of presentation, multi-moda...
-
Duration of androgen deprivation with radio-therapy for high-risk or locally advanced prostate cancer: A network meta-analysis Tumori J. (IF 1.9) Pub Date : 2023-02-09 Fausto Petrelli, Agostina De Stefani, Ivano Vavassori, Federica Motta, Andrea Luciani, Francesca Trevisan
Objective:To evaluate various outcomes of different lengths of androgen deprivation therapy in high- and very-high-risk prostate cancer, we conducted a network meta-analysis of randomized trials. T...
-
Demystifying neuroblastoma malignancy through fractal dimension, entropy, and lacunarity Tumori J. (IF 1.9) Pub Date : 2023-01-16 Irene Donato, Kiran K Velpula, Andrew J Tsung, Jack A Tuszynski, Consolato M Sergi
Purpose:Neuroblastoma is a pediatric solid tumor with a prognosis associated with histology and age of the patient, which are the parameters of the well-established current classification (Shimada ...
-
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients Tumori J. (IF 1.9) Pub Date : 2023-01-06 Beatrice Borelli, Stefania Crucitta, Alessandra Boccaccino, Maria Antista, Carlotta Antoniotti, Federica Marmorino, Daniele Rossini, Veronica Conca, Marco Maria Germani, Leonardo Provenzano, Andrea Spagnoletti, Alberto Giovanni Leone, Federico Cucchiara, Filippo Pietrantonio, Marzia Del Re, Romano Danesi, Gianluca Masi, Chiara Cremolini, Roberto Moretto
Background:Trifluridine/tipiracil and regorafenib are indicated for metastatic colorectal cancer (mCRC) patients’ refractory to standard chemotherapy. No prognostic or predictive biomarkers are ava...
-
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society Tumori J. (IF 1.9) Pub Date : 2023-01-06 Andrea Milani, Valentina Tuninetti, Sandro Pignata, Domenica Lorusso, Daniele Castaldo, Ugo De Giorgi, Antonella Savarese, Nicoletta Biglia, Giuseppa Scandurra, Giorgia Mangili, Massimo Di Maio, Margherita Turinetto, Marco Bellero, Serafina Mammoliti, Silvia Testa, Giulia Scotto, Andrea Purro, Grazia Artioli, Giorgio Valabrega
Introduction:Low molecular weight heparin (LMWH) has been the backbone of the treatment of cancer associated thrombosis (CAT). Direct-acting oral anticoagulants (DOACs) have shown efficacy and safe...
-
Clinical value of offering multiple chemotherapy lines to a luminal-like metastatic breast cancer: A case report with eribulin Tumori J. (IF 1.9) Pub Date : 2022-12-08 Anna Amela Valsecchi, Jessica Paparo, Valeria Pirro, Matteo Manfredi, Massimo Di Maio, Rossana Dionisio
Introduction:The achievement of complete response with chemotherapy after multiple treatment lines in metastatic breast cancer and the chemosensitivity in a luminal-like breast cancer are two impor...
-
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients Tumori J. (IF 1.9) Pub Date : 2022-12-06 Sebastiano Buti, Francesca Trentini, Pierangela Sepe, Melanie Claps, Luca Isella, Elena Verzoni, Giuseppe Procopio
Background:The BONSAI phase II trial recently demonstrated the activity of cabozantinib in metastatic collecting duct patients. The outcomes of patients in this setting treated with immunotherapy a...
-
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03) Tumori J. (IF 1.9) Pub Date : 2022-11-29 Giuseppe Procopio, Mélanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Davide Bimbatti, Franco Nolè, Francesco Carrozza, Sebastiano Buti, Roberto Iacovelli, Chiara Ciccarese, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo de Braud, Elena Verzoni
Background:First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kin...
-
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide Tumori J. (IF 1.9) Pub Date : 2022-11-10 Maria La Vecchia, Ivan Fazio, Nicolò Borsellino, Daniele Galanti, Antonio Lo Casto
Introduction:This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienc...
-
Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options Tumori J. (IF 1.9) Pub Date : 2022-10-31 Spencer H Shao, Brian Allen, Jessica Clement, Gina Chung, Jingjing Gao, Earl Hubbell, Minetta C Liu, Charles Swanton, WH Wilson Tang, Habte Yimer, Mohan Tummala
There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), bu...
-
The distinct experience of supportive care needs among cervical cancer patients: A qualitative study Tumori J. (IF 1.9) Pub Date : 2022-10-31 Kamala Dhakal, Panpan Wang, Joanes Faustine Mboineki, Mikiyas Amare Getu, Changying Chen, Daya Laxmi Shrestha
Introduction:Patients with cervical cancer report experiencing physical, psychological, economic, and social problems daily. An exploration of supportive care needs is important for patients and th...
-
Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect? Tumori J. (IF 1.9) Pub Date : 2022-10-26 Ingrid Garajová, Rita Balsano, Fabio Gelsomino, Francesco Leonardi
Background:Despite ongoing developments, pancreatic cancer remains one of the most difficult tumors to treat. Even the most effective chemotherapy regimens, only marginally improve the outcome of P...
-
Chemo-surgical approach in vulvar leiomyosarcoma: A case report Tumori J. (IF 1.9) Pub Date : 2022-10-14 Giuseppe Capalbo, Alessandra Logoteta, Roberta Gallo, Ilaria Cuccu, Gabriella Gentile, Francesca Arienzo, Angela Musella, Angelina Pernazza, Giorgia Perniola, Violante Di Donato, Lucia Manganaro, Giorgio Bogani, Innocenza Palaia
Introduction:Primary sarcoma of the vulva is an extremely rare entity, representing only 1%–3% of all vulvar malignant neoplasms. Among sarcomas, leiomyosarcoma (LMS) is the most prevalent histolog...
-
The use of PSA testing over more than 20-years: A population-based study in North-Eastern Italy Tumori J. (IF 1.9) Pub Date : 2022-10-10 Martina Taborelli, Federica Toffolutti, Ettore Bidoli, Luigino Dal Maso, Stefania Del Zotto, Elena Clagnan, Michele Gobbato, Diego Serraino, Silvia Franceschi
Objective:To describe the practice of prostate-specific antigen (PSA) testing over more than 20 years in Friuli Venezia Giulia (FVG), North-Eastern Italy.Methods:A population-based, ecological stud...
-
Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review Tumori J. (IF 1.9) Pub Date : 2022-09-27 Andrea Luciani, Antonio Ghidini, Karen Borgonovo, Maria Chiara Parati, Fausto Petrelli
Patients whose tumours harbour epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) driver mutations can benefit most from treatment with tyrosine kinase inhibitors (TKIs)....
-
Corrigendum to: AIRO Breast Cancer Group Best Clinical Practice 2022 Update Tumori J. (IF 1.9) Pub Date : 2022-09-20
-
Establishment of 6 pediatric rhabdomyosarcoma patient’s derived xenograft models closely recapitulating patients’ tumor characteristics Tumori J. (IF 1.9) Pub Date : 2022-09-16 Patrizia Gasparini, Michela Casanova, Giovanni Centonze, Cristina Borzi, Luca Bergamaschi, Paola Collini, Adele Testi, Stefano Chiaravalli, Maura Massimino, Gabriella Sozzi, Andrea Ferrari, Massimo Moro
Introduction:The prognosis for patients with metastatic and recurrent pediatric rhabdomyosarcoma (RMS) remains poor. The availability of preclinical models is essential to identify promising treatm...
-
CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice Tumori J. (IF 1.9) Pub Date : 2022-09-15 Raffaella D’Onofrio, Francesco Caputo, Francesco Prampolini, Andrea Spallanzani, Fabio Gelsomino, Stefania Bettelli, Samantha Manfredini, Luca Reggiani Bonetti, Pietro Carotenuto, Alessandro Bocconi, Massimo Dominici, Gabriele Luppi, Massimiliano Salati
Aim:To apply extended ctDNA-based RAS genotyping to clinical criteria for improving the selection of patients eligible for anti-EGFR-based rechallenge in a real-world setting.Methods:ctDNA testing ...